We investigated the administration of i.v. BU combined with melphalan (Mel) in patients with ALL undergoing allogeneic hematopoietic SCT. Forty-seven patients with a median age of 33 years (range 20-61) received a matched sibling (n ¼ 27) or matched unrelated donor transplant (n ¼ 20) for ALL in first CR (n ¼ 26), second CR (n ¼ 13), or with more advanced disease (n ¼ 8). BU was infused daily for 4 days, either at a fixed dose of 130 mg/m 2 (5 patients) or using pharmacokinetic (PK) dose adjustment (42 patients), to target an average daily area-under-the-curve (AUC) of 5000 mmol/min, determined by a test dose of i.v. BU at 32 mg/ m 2 . This was followed by a rest day, then two daily doses of Mel at 70 mg/m 2 . Stem cells were infused on the following day. The 2-year OS, PFS and non-relapse mortality (NRM) rates were 35% (95% confidence interval (CI), 23-51%), 31% (95% CI, 21-48%) and 37% (95% CI, 23-50%), respectively. Acute NRM at 100 days was favorable at 12% (95% CI, 5-24%); however, the 2-year NRM was significantly higher for patients older than 40 years, 58% vs 20%, mainly due to GVHD.
INTRODUCTION
Allogeneic hematopoietic SCT is an effective, potentially curative treatment option for adults with ALL. Survival rates range broadly from 20 to 60%, depending primarily on disease status at the time of transplant. 1 Non-relapse mortality (NRM) remains a major problem, occurring in 20-45% of patients receiving a standard, radiation-based, myeloablative preparative regimen. [1] [2] [3] The results of the MRC/ECOG trial underscored the impact of NRM. This randomized trial was designed to investigate the efficacy of TBI and etoposide with allo-SCT as compared with continued chemotherapy in adult patients with ALL in first remission. Although allo-SCT afforded significantly better protection against disease relapse and better OS for the transplant group (53% vs 45%, P ¼ 0.01), the 2-year NRM rate of 36% in high-risk patients obviated any survival benefit for this group. High-risk was defined as an elevated WBC count at diagnosis, age 435 years or the presence of the Ph chromosome. 3 In an effort to reduce the toxicities associated with TBI and allo-SCT, [4] [5] [6] [7] we investigated a non-radiation-based, myeloablative preparative regimen for adult patients with ALL.
Alkylating agents form the backbone of most transplant preparative regimens. Several groups have evaluated the combination of BU and melphalan (Mel). Both of these agents are directly active and display linear pharmacokinetics (PK) in the dose ranges utilized with hematopoietic transplantation. [8] [9] [10] Both agents penetrate into the central nervous system (CNS). 11 Myelosuppression is the primary toxicity of both drugs and the non-hematopoietic toxicity profiles are generally non-overlapping. This myeloablative combination has been studied in patients with a wide range of advanced hematologic malignancies in both the autologous [12] [13] [14] [15] and allogeneic setting. [16] [17] [18] [19] [20] Small et al. 17 studied 43 patients with advanced leukemia (5 with ALL), including 34 with active disease and a reported 3-year OS of 37%. Importantly, the NRM at 30 days and 100 days were 0 and 16%, respectively.
Once daily i.v. BU administration has been noted to be safe. 21 There is linear PK, with highly reproducible intra-and inter-patient systemic exposure; 10 this has allowed the identification of an optimized therapeutic interval. 22 Based on these considerations, we hypothesized that i.v. BU administered once daily for 4 days with PK guidance, followed by Mel administered over 2 days, would constitute a safe and effective myeloablative regimen in patients undergoing allo-SCT for ALL.
PATIENTS AND METHODS

Patient eligibility
This was a prospective, phase II single-arm study conducted between August 2005 and October 2009 investigating the combination of i.v. BU and Mel in patients with ALL. Patients were required to be between 18 and 65 years of age, with an HLA-matched related or unrelated donor (defined as an HLA-A, B serologic-matched and DRB1 molecular matched donor). Additional eligibility criteria included a creatinine clearance of X60 mL/ min, alanine aminotransferase p3 times the upper normal limit, a Zubrod performance status of 0 or 1, no evidence of uncontrolled infection, and negative serology for hepatitis B, C and HIV. Patients were required to have adequate cardiac function demonstrated by left ventricular ejection fraction X40%, and good lung function demonstrated by forced expiratory volume in 1 second, forced vital capacity and diffusing capacity of lung for CO 2 corrected for hemoglobin of more than 50% of predicted. Patients with active CNS disease were excluded. 1 
Preparative regimen
The transplant preparative regimen consisted of i.v. BU administered either as a fixed dose of 130 mg/m 2 infused over 3 h once daily for 4 days or to target an average daily AUC of 5000 mmol/min ± 12%. In a prior study, we demonstrated that a daily BU dose of 130 mg/m 2 produced a median daily AUC of approximately 4900 mmol/min; 23 patients had the option of receiving either a fixed dose or PK-directed dosing. The therapeutic dose was determined by the drug clearance rate, which was in turn determined by PK testing using a test dose of i.v. BU administered at 32 mg/m 2 and infused over 45 min approximately 48 h before the first therapeutic BU dose. If necessary, a second BU dose adjustment was made following the first therapeutic dose analysis in an effort to keep the total course AUC at 20 000 mmol/min. Collection of blood and methods for PK analyses were performed as previously reported. 10, 14, 24 The BU administrations were followed by a rest day to allow for glutathione repletion, and Mel was administered at a fixed dose of 70 mg/m 2 infused over 30 min once daily for 2 days. The allogeneic progenitor cells were infused on the following day.
Patients who were Ph þ , and were in molecular remission after SCT, were started on maintenance therapy with imatinib mesylate upon normalization of blood counts following SCT to continue for 1 year; patients in continued molecular remission at 1 year following SCT stopped TKI, but those with persistent minimal residual disease stayed on treatment.
Donors
All donors were HLA-A, -B, and -DR compatible with the patients. HLA typing for class I Ags was performed using standard serologic or lowresolution molecular techniques, followed by high-resolution molecular typing using PCR for class I and II Ags for confirmatory typing of sibling donors; high-resolution molecular typing of class I and II Ags was performed for all unrelated donors.
Peripheral blood stem cells were obtained from donors using standard mobilization protocols and apheresis techniques, with a target progenitor cell dose of 4 Â 10 6 CD34 þ cells/kg and minimal acceptable dose of 2 Â 10 6 CD34 þ cells/kg; BM was used if peripheral blood could not be used. Stem cells from all related donors were collected at the MD Anderson Cancer Center. Peripheral blood progenitor cells or BM harvests from unrelated donors was obtained through the National Marrow Donor Program.
Supportive care
Phenytoin 600 mg orally was used during and 1 day after completion of i.v. BU therapy, starting the evening before the first dose. 25 GVHD prophylaxis consisted of a combination of tacrolimus and MTX. MTX (5 mg/m 2 ) was given i.v. on days þ 1, þ 3, þ 6 and þ 11. Tacrolimus was administered at a dose sufficient to maintain levels between 5-15 ng/mL, and tapered at the discretion of the treating physician. Patients who received unrelated donor products additionally received rabbit anti-thymocyte globulin for a total 4 mg/kg infused over 3 days beginning 3 days prior to SCT. Patients who experienced grade II or higher acute GVHD received i.v. methylprednisolone at a dosage of at least 0.5 mg/kg every 6 h and, if possible, were enrolled in treatment protocols for GVHD.
Institutional transplant guidelines for antimicrobial, antifungal and antiviral prophylaxis were followed as previously reported. 26 
Definitions and clinical outcome variables
Criteria for complete response included normal cytogenetics, the absence of circulating blasts, o5% marrow blasts and a platelet count of 100 Â 10 9 /L or higher. Standard morphologic criteria, conventional cytogenetic analysis by G-banding or both were used to diagnose recurrent disease. The disease stage at transplantation was defined using established criteria. Response was documented as best response occurring after day 30 following SCT. Molecular response measured by quantitative PCR analysis for BCR-ABL rearrangement was obtained when possible. Hematologic recovery was defined as having an ANC of 0.5 Â 10 9 /L or higher for 3 consecutive days. Platelet recovery was defined as having a platelet count of 20 Â 10 9 /L or higher for 7 consecutive days without transfusion support. Failure to engraft by day þ 30 was considered primary engraftment failure. Hematopoietic chimerism was evaluated in BM (using unsorted cells) or peripheral blood (with myeloid and T-lineage sorting) by RFLP using PCR methods to determine donor engraftment. Mixed chimerism was defined as the presence of any detectable (X1%) recipient DNA in addition to donor-derived DNA in myeloid or T-lineage cells.
OS was estimated from the time of SCT until death from any cause, and patients still alive at last follow-up were considered censored. PFS was estimated from SCT until the date of progression or death from any cause. Patients alive and progression free at last follow-up were considered censored. NRM was defined as death from any cause other than disease progression or relapse. The diagnosis of GVHD was confirmed by biopsy when feasible but was ultimately determined by clinical presentation. Acute GVHD was clinically graded as 0-IV based on standard criteria; 27 chronic GVHD was classified as none, limited or extensive. 28 Acute GVHD, which persisted or progressed after day 100, was also scored as chronic GVHD in this study.
Statistical methods
The primary outcomes for this single-arm trial were safety and OS. Bayesian early stopping rules based on the observed rates of these two outcomes, as compared with historical data, were implemented. 29 The Kaplan-Meier estimator 30 was used to assess OS and PFS probabilities in months. OS or PFS distributions were compared between subgroups using the log-rank test. 31 Descriptive statistics were used to summarize patient demographics.
RESULTS
Patient and treatment characteristics
Patient demographics and baseline disease characteristics are listed in Table 1 . Forty-seven patients with a median age of 33 years (range 20-61) were evaluated on this study. The median number of prior treatment regimens was 2 (range 1-4), with a One patient received prior allo-SCT.
BU plus Mel for allo-SCT in ALL P Kebriaei et al median of 12 months from the time of diagnosis to transplant. The majority of patients had high-risk features at diagnosis, with 30% (n ¼ 14) having an elevated WBC count at diagnosis, 45% (n ¼ 21) having the Ph chromosome and 49% (n ¼ 23) taking 44 weeks to achieve first remission. At the time of transplant, 55% (n ¼ 26) were in CR1, 28% (n ¼ 13) were in CR2, and 18% (n ¼ 8) were beyond CR2 or had active disease. Seven patients had extramedullary involvement of disease at the time of diagnosis. Eightynine percent of patients (n ¼ 42) had PK-directed BU dosing. Eleven patients with Ph þ ALL were started on a median dose of 200 mg imatinib (range 100-400) maintenance therapy at a median of 2 months (range 1-5) following SCT. Three patients remain on imatinib due to fluctuating levels of minimal residual disease, four patients stopped imatinib after completing 1 year of maintenance, one patient stopped after 1 month due to thrombocytopenia, and three patients stopped due to disease progression. The remaining 10 patients with Ph þ ALL were not able to receive intended maintenance due to low counts in the setting of active GVHD or infection. Of note, all of the Ph þ patients received imatinib as part of their therapy prior to SCT.
Graft content and engraftment Stem cell graft characteristics and hematopoietic recovery data are summarized in Table 2 . Approximately half of the patients received a matched-related-donor transplant (57%) and the remaining matched-unrelated-donor SCT (43%). The source of stem cells was peripheral blood for the majority of patients. The median TNC count and CD34 þ cell doses were 7 Â 10 8 /kg (range 1-23) and 5 Â 10 6 /kg (range 1-14), respectively. The median time to neutrophil and platelet recovery were 11 (range 10-22) and 13 days (range 8-61), respectively. OS Fourteen patients were alive at a median follow-up of 38 months (range 7-77) among survivors, with 1-and 2-year OS rates of 46% (95% confidence interval (CI), 34-63%) and 35% (95% CI, 23-51%), respectively. As expected, patients in CR1 or CR2 had significantly better outcomes than patients with more advanced disease at the time of transplant, with none of the eight patients transplanted beyond CR2 remaining alive (Figure 1 ).
Response, relapse and PFS One patient had an early death at 20 days following transplant due to pulmonary hemorrhage; thus, 46 patients were evaluable for response. All patients maintained or achieved CR. All except one patient achieved 100% donor engraftment at a median of 32 days (range 25-47) following SCT; one patient remained in mixed chimera with 97% donor cells by unsorted chimerism analysis in BM, and 99% donor cells in myeloid lineage and 30% donor in T-lineage cells by cell-sorted-chimerism analysis in peripheral blood, and eventually relapsed 5 months following transplant. Thirty-five patients relapsed or died at a median of 6 months (95% CI, 5-22) following SCT, with 1-and 2-year PFS rates of 43% (95% CI, 31-59%) and 31% (95% CI, 21-48%), respectively. Again, PFS for patients transplanted in CR1 or CR2 was significantly better than for patients transplanted with advanced disease (Figure 2 ). The incidence of progression for the entire group at 1 and 2 years was 26% (95% CI, 14-39%) and 32% (95% CI, 19-46%), respectively. The incidence of progression in CR1 patients was lower, at 19% (95% CI, 7-36%) and 23% (95% CI, 9-41%) at 1 and 2 years, respectively. Six patients had an extramedullary site of disease at the time of relapse; four had BM relapse concurrent with extramedullary relapse and two patients had an isolated relapse (stomach and cheek). Among these six patients, four had a history of extramedullary disease prior to transplant.
Toxicity, NRM and GVHD Regimen-related toxicities are detailed in Table 3 . The most commonly observed toxicities involved the GI tract, and were grades I or II nausea and vomiting (94%), mucositis (70%) and diarrhea (57%). Nineteen percent of patients developed reversible BU plus Mel for allo-SCT in ALL P Kebriaei et al transaminitis or hyperbilirubinemia. One patient, with multiple lines of prior therapy, developed grade 4 bilirubin elevation beginning at day 4 of the transplant conditioning regimen, peaking at 40 mg/dL at the time of his death at day 46 following SCT from candidemia lusitaniae (identified post mortem) hepatic infiltration, sepsis and multi-organ failure. Two patients developed reversible veno-occlusive disease of the liver, ascertained using Jones' criteria, 32 at 24 days and 33 days following SCT. There were two cases of grade 2 diffuse alveolar hemorrhage without isolation of definite infectious causes, which responded to steroid therapy. One fatal case of diffuse alveolar hemorrhage occurred within 30 days of the transplant conditioning regimen in a 52-year-old patient who had received a matched unrelated donor transplant. Significant CNS toxicity was not observed, but one patient who was unable to take his prophylactic phenytoin because of nausea and vomiting suffered a seizure. The cumulative incidences of NRM at 100 days, 1 year and 2 years were 13% (95% CI, 5-24%), 32% (95% CI, 19-46%) and 37% (95% CI, 23-50%), respectively. NRM was significantly higher in patients more than 40 years old (Figure 3 ). There were 33 deaths, with primary causes being infection (n ¼ 2), multi-organ failure (n ¼ 1), diffuse alveolar hemorrhage (n ¼ 1), recurrent breast cancer (n ¼ 1), acute GVHD (n ¼ 8), chronic GVHD (n ¼ 4) or relapse (n ¼ 16).
The cumulative incidence of grades II-IV and III-IV acute GVHD were 54% and 26%, respectively; there was no statistically significant difference between matched related and unrelated donors. The cumulative incidence of chronic GVHD was 40%, with 26% experiencing extensive GVHD. Again, no difference was noted between allotypes (Table 4) .
DISCUSSION
This is a large, single-institution series of adult patients with highrisk ALL treated with a myeloablative, non-radiation based, transplant preparative regimen, with relatively long follow-up. The eradication of minimal residual disease in 11 patients and the clearance of active disease in three patients at the time of transplant attest to the anti-leukemic activity of the BU and Mel combination, which has been demonstrated in children and adults with advanced myeloid and lymphoid malignancies. 12, 13, 33, 34 Importantly, despite our high-risk patient population, including 45% Ph þ patients, and a median of 12 months from diagnosis to transplant, our 2-year OS rates of approximately 40% for patients in first or second remission were comparable to the survival rates reported in the CIBMTR registry study of patients transplanted in CR1 or CR2 using mainly TBI-based (88%) preparative regimens. 34 One important concern is the control of 'sanctuary' sites with a non-TBI regimen. We noted one case of CNS relapse concurrent with marrow relapse in a patient with T-lineage ALL with a prior history of mediastinal mass and lymphadenopathy, and one case of testicular relapse concurrent with marrow relapse in a patient with prior history of testicular involvement and radiation therapy to the testes. These rates appear comparable to TBI-containing regimens, but our study population is too small to fully address this question.
Approximately 50% of our Ph þ patients received posttransplant imatinib maintenance therapy. Similar to our previous reported findings, the use of imatinib maintenance did not appear to impact the PFS rate (data not shown). 25 Our regimen was well tolerated with an early NRM rate of 12% at 100 days. Furthermore, in our 12 patients up to age 35 years (26) and transplanted in CR1, our 2-year NRM rate was only 8% compared with 20% for a much larger patient cohort, but with characteristics similar to those reported in the MRC-ECOG trial. 3 We postulated that using i.v., PK-guided BU, which allows for more precise dose delivery with a tighter range in systemic drug exposure, would result in decreased regimen-related toxicity. The assumed benefits from PK-directed BU dosing were extrapolated from our previous observations of an optimal therapeutic interval for BU within the window of 3800-6080 mmol/min. 22 Thus, we targeted a (median) daily dose AUC of 5000 mmol/min for the present study. We noted prompt engraftment in all patients, no unexpected toxicities, and only two cases of reversible venoocclusive disease in two heavily pre-treated patients. This favorable toxicity profile is in distinct contrast to the toxicities of fatal veno-occlusive disease in earlier studies that used oral BU. 12, 16, 35 As expected, there was a higher risk of NRM in older patients. In patients 440 years old, there was one regimen-related death resulting from pulmonary hemorrhage at 17 days following transplant, and the NRM rate was 55% at 2 years ( Figure 3) . Increased rates of GVHD accounted for the higher, late NRM noted in this population. The rate of grades 2-4 acute GVHD was 65% in older patients, compared with 46% in patients up to age 40 years. The incidence of GVHD was comparable to that reported by Marks et al. 36 for ALL patients receiving myeloablative SCT regimens. Of the 21 patients 440 years old, 9 of the 12 deaths were related to acute or chronic GVHD. The incidence of chronic extensive GVHD was similar in both age groups.
In conclusion, we have demonstrated the efficacy of a chemotherapy-only preparative regimen for allo-SCT in patients with high-risk ALL. These findings corroborate recently published results of i.v. BU combined with cyclophosphamide with excellent disease control, and low TRM with the replacement of i.v. for oral BU historically used in this regimen. 37 As we continue to build on these results, we will need to 'personalize' treatment approaches for patients by modifying the treatment intensity based on patient and disease characteristics, to optimize overall outcomes. Leukemia relapse remains the major cause of treatment failure with a high rate of progression in the younger patients (Figure 4) , while GVHD remains a major problem in older patients. Thus, in our current transplant protocol for ALL patients, we target a higher daily BU AUC of 5500 mmol/min for younger patients and lower AUC of 4000 mmol/min for older patients. Furthermore, based on in vitro 38 and in vivo 21, 23, 39, 40 studies suggesting favorable synergy between nucleoside analogs and BU, we have replaced Mel with clofarabine in an effort to reduce GI and pulmonary toxicity, while possibly improving anti-ALL activity. 41, 42 Early observations are encouraging. 43 Further modifications will be needed to better control GVHD. 
